If you’ve been tracking Biomedical Advanced Research and Development Authority (BARDA) activity solely through SAM.gov, some opportunities may be easy to miss. Yes, traditional funding and contracting mechanisms, like BAAs and RFPs, continue to be pushed by BARDA – and will continue to do so for some time – but the agency is also making
BARDA’s Growing Use of Hubs and Prize Competitions, Beyond SAM.gov Read More »
The Rapid Response Partnership Vehicle (RRPV) consortium, through the Biomedical Advanced Research and Development Authority (BARDA), convenes government, industry, academic, nonprofit, and service-provider organizations working to accelerate medical countermeasures for emerging infectious diseases and other national preparedness priorities. EverGlade team members Laura Powell, PhD, PMP, and Richard Merlino, MBA attended last week’s General Membership Meeting
Four Takeaways from the 2026 RRPV General Membership Meeting Read More »
The Biomedical Advanced Research and Development Authority (BARDA), through the Rapid Response Partnership Vehicle (RRPV), has released a pre-solicitation notice for a potential future project opportunity: TACTIC, or Threat-Agnostic CBRN Therapeutics. The anticipated effort would support development of therapeutics that address host dysregulation caused by chemical, biological, radiological, and nuclear, or CBRN, threats. BARDA is
BARDA Previews TACTIC Program for Threat-Agnostic CBRN Therapeutics Read More »
The Biomedical Advanced Research and Development Authority (BARDA) has released a draft Request for Project Proposals (RPP), RRPV 26-05-NVP: “New Vaccine Platforms,” through the Rapid Response Partnership Vehicle (RRPV). The draft opportunity seeks mature, adaptable vaccine platform technologies that can help the United States prepare for emerging infectious disease threats before and during public health
The Biomedical Advanced Research and Development Authority (BARDA) has released a new Request for Proposals, Vaccine Medical Countermeasures for Pandemic Influenza Preparedness and Response. The solicitation seeks partners to support the development, manufacturing, stockpiling, regulatory readiness, and rapid deployment of influenza vaccine medical countermeasures during a pandemic or other public health emergency. BARDA’s objective is
BARDA Releases RFP for Pandemic Influenza Vaccine Medical Countermeasures Read More »
The Biomedical Advanced Research and Development Authority (BARDA), through the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP-Consortium), has released Request for Project Proposals (RPP) 26-12-VMI, “Ensuring American Pharmaceutical Supply Chain Resilience through Vendor Managed Inventory Capabilities for Active Pharmaceutical Ingredients Used in Medical Countermeasure Finished Dose Form Drug Products.” Issued by the Administration for Strategic Preparedness and
The Biomedical Advanced Research and Development Authority (BARDA) has been telegraphing its priorities for years, but the latest cluster of moves makes the picture sharper: the U.S. is shifting from “buy vaccines when a crisis hits” to owning the infrastructure that keeps pandemic response on a hair trigger. Three signals stand out: A new pre‑solicitation
BARDA’s Next Big Investment Play: Pandemic Preparedness And Domestic Manufacturing Read More »
ASPR And BARDA Move To Close The Nitrile Glove Gap The Biomedical Advanced Research and Development Authority (BARDA), through the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP‑Consortium), has released a new Request for Project Proposals (RPP 26‑09‑Gloves) focused on Expansion of Domestic Manufacturing Capacity for Nitrile Gloves. ASPR’s Center for Industrial Base Management and Supply Chain (IBMSC)
BARDA’s BioMaP Releases RPP on Domestic Manufacturing for Nitrile Gloves Read More »
The Biomedical Advanced Research and Development Authority (BARDA), working through the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP‑Consortium), has released a new Request for Project Proposals (RPP 26‑04‑NBR) focused on Sustainment of PPE Capacities – Nitrile Butadiene Rubber (NBR). ASPR’s Industrial Base Management and Supply Chain (IBMSC) is seeking projects that will sustain and strengthen domestic NBR
Sustaining Nitrile Glove Capacity With BARDA’s PPE Manufacturing Push Read More »
The Biomedical Advanced Research and Development Authority (BARDA) has quietly dropped a pre‑solicitation notice for a major, long‑term contract to sustain and expand the Vaccine Medical Countermeasures (MCMs) for Pandemic Influenza Preparedness and Response Program, including the U.S. National Pre‑pandemic Influenza Vaccine Stockpile (NPIVS). The notice, posted July 30, 2026 under solicitation number 75A50126R00001, is
BARDA Signals Major NPIVS Contract For Pandemic Influenza Vaccines And Adjuvants Read More »
The Biomedical Advanced Research and Development Authority (BARDA) has issued a Sources Sought Notice titled “Advanced Dermal Regeneration Substitutes for Treatment of Severe Burns and Complex Traumatic Injuries” (BARDA-CBRN-07282026) to identify commercially available or near commercial technologies that address large-area skin loss from burns and traumatic injuries in a mass casualty setting. This notice is for
BARDA Seeks Advanced Dermal Regeneration Solutions for Severe Burns Read More »
Overview of the Opportunity The Biomedical Advanced Research and Development Authority (BARDA), through the Rapid Response Partnership Vehicle (RRPV), has released a new Request for Information (RFI) titled “Biosafety Level 4 Preclinical and Nonclinical Support for Medical Countermeasure Development (BSL4)”. Issued July 9, 2026, the RFI is a market research exercise to map out who can deliver preclinical and nonclinical
BARDA RRPV RFI Seeks Partners for BSL4 Studies and Support Services Read More »
